Solid Biosciences Inc. sponsors SADS Foundation symposium to back genetic heart rhythm research

Solid Biosciences Inc. sponsors SADS Foundation symposium to back genetic heart rhythm research
Solid Biosciences backs arrhythmia event

Solid Biosciences Inc. participated in and sponsored the SADS Foundation’s Challenging Cases in Inherited Arrhythmias Symposium and Reception last week.

The company emphasized its commitment to advancing research and raising awareness about genetic heart rhythm conditions. Attending the event underscores Solid Biosciences Inc.'s engagement with leading foundations addressing cardiac genetics. Details of the collaboration and future projects were not disclosed.

Earlier this year, Solid Biosciences announced advancements in precision gene therapy at a major symposium, including new targeting strategies. The company also initiated human trials for its SGT-212 gene therapy, addressing both neuromuscular and cardiac conditions such as Friedreich ataxia in clinical studies. These initiatives highlight the company's focus on genetic approaches to treat inherited disorders.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.